I am the Director of the Center for Thoracic Cancers at the Massachusetts General Hospital (MGH), Director of Targeted Immunotherapy in the Henri and Belinda Termeer Center for Targeted Therapies, and Co-Leader of the SU2C Lung Cancer Dream Team. My major research interests have centered around two themes: targeted therapy and immunotherapy. Currently, I am the principal investigator of multiple clinical trials evaluating novel targeted therapies among patients with oncogene-driven lung cancers, with a particular focus on oncogenic fusions involving anaplastic lymphoma kinase (ALK) and RET. To complement these efforts, I have also led efforts to define the molecular mechanisms of resistance to targeted therapies.
More recently, I have worked to transfer the same clinical-translational research framework pioneered in targeted therapies to the immunotherapy setting. My early efforts in this regard have focused on exploring the activity of immune checkpoint inhibitors among patients with oncogene-driven lung cancers. Our current research focus is to elucidate predictors of response and resistance to immune checkpoint inhibitors. These translational studies are complemented by a robust portfolio of phase I/II trials examining novel immunotherapy combinations